ABSTRACT
Background: The consumption of EPA (Eicosapentaenoic acid), and DHA (docosahexaenoic acid), from fish oil, in the long run, has been observed to have a positive impact on patients with coronary heart disease. Fish oil products, with so much EPA and DHA content are available, and have very variable prices. Therefore, as a therapy to be used for long-term treatment, the cost factor is to be considered.
Design and methods: This study analyzed the content of EPA and DHA, using GC-MS. The sample to be analyzed was the fish oil that has the lowest price (Product A1), and that of the highest (Product A2). Furthermore, the macroscopic analysis was performed, by observing the physical form including organoleptic and qualitative tests, by reading the fragments identified by EPA and DHA.
Results: Clinical trials were conducted on patients (about 46 people), with risk factors and dyslipidemia. Product A1 showed EPA at tR= 15.574 min (relative%= 88.49%, similarity= 95%), and DHA at tR= 21.714 min (relative%= 88.92%, similarity= 93%). Product A2 showed EPA at tR= 28.719 min (relative%= 22.58%, similarity= 89%), and DHA at tR= 32.327 min (relative%= 22.87%, similarity= 90%), which meant that both had EPA and DHA contents, in accordance with their labels. Both products were confirmed to reduce total cholesterol in 4weeks (p=0.000, p= 0.000), with no significant difference in their effectiveness (p=0.652).
Conclusion: The results showed that both the A1 and A2 products, had the EPA and DHA contents in accordance with their respective labels. However, with the A2 product having a percentage relatively higher than that of the A1 brand, both are equally very effective.
REFERENCES
Word Health Organization. Cardiovascular Disease. Geneva: Word Health Organization; 2019.
Ministry of Health Republic of Indonesia. Riset Kesehatan Dasar (RISKESDAS) 2013 (Basic Health Research 2013)].[in Indonesian]. Jakarta: Ministry of Health Republic of Indonesia; 2013.
Center for Data and Information of the Ministry of Health of the Republic of Indonesia. [Situasi Kesehatan Jantung (Heart health situation)].[in Indonesian]. Jakarta: Ministry of Health Republic of Indonesia; 2014.
Kones R. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management: A comprehensive survey. Drug Des Dev Ther 2011;5:325–80. DOI: https://doi.org/10.2147/DDDT.S14934
Goldberg IJ, Trent C, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab 2012;15:805–12. DOI: https://doi.org/10.1016/j.cmet.2012.04.006
Mathes P, Thiery J. The role of lipid metabolism in the prevention of coronary heart disease. Z Kardiol 2005;94:43–55.
Hayes J, Benson G. What the latest evidence tells us about fat and cardiovascular health. Diabetes Spectr 2016;29:171–5. DOI: https://doi.org/10.2337/diaspect.29.3.171
Siri-Tarino PW, Chiu S, Bergeron N, et al. Saturated fats versus polyunsaturated fats versus carbohydrates for cardiovascular disease prevention and treatment. Annu Rev Nutr 2015;35:517–43. DOI: https://doi.org/10.1146/annurev-nutr-071714-034449
Calvo MJ, Martinez MS, Torres W, et al. Omega-3 polyunsaturated fatty acids and cardiovascular health: a molecular view into structure and function. Vessel Plus 2017;1:116–28. DOI: https://doi.org/10.20517/2574-1209.2017.14
Veno SK, Bork CS, Jakobsen MU, et al. Marine n-3 polyunsaturated fatty acids and the risk of ischemic stroke. Stroke 2019;50:274–82. DOI: https://doi.org/10.1161/STROKEAHA.118.023384
Fournier V, Juanéda P, Destaillats F, et al. Analysis of eicosapentaenoic and docosahexaenoic acid geometrical isomers formed during fish oil deodorization. J Chromatogr A 2006;1129:21–8. DOI: https://doi.org/10.1016/j.chroma.2006.06.089
Abdelhamid AS, Martin N, Bridges C, et al. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018;7:CD012345. DOI: https://doi.org/10.1002/14651858.CD012345.pub3
Khandelwal S, Kelly L, Malik R, et al. Impact of omega-6 fatty acids on cardiovascular outcomes: A review. Preventive Cardiol 2013;2:325–36.
Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res 2012;53:2525-45. DOI: https://doi.org/10.1194/jlr.R027904
Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr 2012;3:1-7. DOI: https://doi.org/10.3945/an.111.000893
Bradberry JC, Hilleman DE. Overview of omega-3 fatty acid therapies. PT 2013;38:681-91.
Osamor PE, Owumo BE. Factors associated with treatment compliance in hypertension in Southwest Nigeria. J Health Popul Nutr 2011;29:619–28.
Tarride JE, Lim M, Meules MD, et al. A review of the cost of cardiovascular disease. Can J Cardiol 2009;25:e195–202. DOI: https://doi.org/10.1016/S0828-282X(09)70098-4
Ko HY, Lee JK, Shin JY, et al. Health-related quality of life and cardiovascular disease risk in Korean adults. Korean J Fam Med 2015;36:349–56. DOI: https://doi.org/10.4082/kjfm.2015.36.6.349
Yi T, Li SM, Fan JY, et al. Comparative analysis of EPA and DHA in fish oil nutritional capsules by GC-MS. Lipids Health Dis 2014;13:1–6. DOI: https://doi.org/10.1186/1476-511X-13-190
Bratu A, Mihalache M, Hanganu A, et al. Quantitative determination of fatty acids from fish oils using GC-MS method and H-NMR spectroscopy. UPB Sci Bull B 2013;75:23-32.
Medscape [Internet]. Framingham 10 year risk of general cardiovascular disease (2008) [updated 2020 Nov; cited 2020 Nov 10]. Available from: Available from: https://reference.medscape.com/calculator/framingham-cardiovascular-disease-risk
Hajar R. Risk factors for coronary artery disease: Historical perspectives. Heart Views 2017;18:109–14. DOI: https://doi.org/10.4103/HEARTVIEWS.HEARTVIEWS_106_17
So JH, Lee JK, Shin JY, et al. Risk of cardiovascular disease using Framingham risk score in Korean cancer survivors. Korean J Fam Med 2016;37:235–41. DOI: https://doi.org/10.4082/kjfm.2016.37.4.235
D’Agostino RB, Pencina MJ, Massaro JM, et al. Cardiovascular disease risk assessment: Insights from Framingham. Global Heart 2013;8:11–23. DOI: https://doi.org/10.1016/j.gheart.2013.01.001
Indonesian Association of Cardiovascular Specialists. Panduan Tata Laksana Dislipidemia 2017 (Guidelines for Dyslipidemia Management 2017)].[in Indonesian]. Available from: http://www.inaheart.org/upload/image/lipid.pdf
Peters SAE, Munther P, Woodward M. Sex differences in the prevalence of, and trends in, cardiovascular risk factors, treatment, and control in the United States, 2001 to 2016. Circulation 2019;139:1025–35. DOI: https://doi.org/10.1161/CIRCULATIONAHA.118.035550
Safford MM, Gamboa CM, Durant RW, et al. Race–sex differences in the management of hyperlipidemia. Am J Prev Med 2015;48:520–7. DOI: https://doi.org/10.1016/j.amepre.2014.10.025
Cho SMJ, Lee HJ, Shim JS, et al. Associations between age and dyslipidemia are differed by education level: The Cardiovascular and Metabolic Diseases Etiology Research Center (CMERC) cohort. Lipids Health Dis 2020;19:1–12. DOI: https://doi.org/10.1186/s12944-020-1189-y
Nejad AM, Bikdeli B. Omega-3 supplements and cardiovascular disease. Tanaffos 2014;13:6–14.
Zibaeenezhad MJ, Ghavipisheh M, Attar A, et al. Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial. Nutr Diabetes 2017;7:1–8. DOI: https://doi.org/10.1038/s41387-017-0007-8
Colussi G, Catena C, Novello M, et al. Impact of omega-3 polyunsaturated fatty acids on vascular function and blood pressure: Relevance for cardiovascular outcomes. Nutr Metab Cardiovasc Dis 2017;27:191–200. DOI: https://doi.org/10.1016/j.numecd.2016.07.011
Pizzini A, Lunger L, Demetz E, et al. The role of omega-3 fatty acids in reverse cholesterol transport: A review. Nutrients 2017;9:1–12. DOI: https://doi.org/10.3390/nu9101099